Thyrocare Technologies posted a good set of numbers this quarter. In an interview to CNBC-TV18, A Velumani, Chairman, MD & CEO of Thyrocare Technologies discussed the company's Q1 performance.
I am happy that we have done better than the market. This is a market where competitors are growing (number wise) more than the market, said Velumani.
According to him, current business model probably is correct in lieu of competition.
He said goods and services tax (GST) will not improve or decrease market share.
Velumani sees around 25 percent growth in compound annual growth rate (CAGR) in revenue.
Thyrocare opened eight regional processing labs which added to growth, he said.
"Preventive care segment is growing around 40 percent year-on-year (YoY) compared to sickness industry which grows around 15 percent," he added.
Would look to add four more regional processing labs, said Velumani.
Watch accompanying video for more details.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
